Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics, Incorporated announced its Annual Meeting of Stockholders will take place on Wednesday, May 27, 2026, at 10:00 AM Pacific Time at the company's South San Francisco headquarters. Following the meeting, President and CEO Robert I. Blum will provide a performance overview. Stockholders as of March 31, 2026, are eligible to vote.
Cytokinetics (CYTK) Valuation Check After Strong Multi Year Returns And Late Stage Pipeline Progress
Cytokinetics (CYTK) has shown strong multi-year returns and significant recent gains, with its shares closing at $78.77. Simply Wall St's analysis suggests the stock is currently undervalued at $92.94, based on aggressive growth assumptions for its late-stage pipeline and muscle biology platform. However, this valuation depends on positive trial data and successful commercial uptake of Myqorzo, with investors advised to consider both the potential upside and key risks.
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK)
Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (CYTK), sold 3,500 shares of the company on May 19, 2026. This transaction follows a pattern of insider selling, with 71 insider sells and no buys recorded for CYTK over the past year. The stock is currently trading at $75.69, which is significantly below its GF Value of $247.54, leading GuruFocus to classify it as a "Possible Value Trap, Think Twice."
Cytokinetics (CYTK) R&D EVP exercises options and sells 3,500 shares
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc. (CYTK), exercised stock options for 3,500 shares at $7.80 per share and subsequently sold those 3,500 shares on the open market at an average price of $75.69 per share on May 19, 2026. This transaction is considered a routine liquidity event, as Malik still holds a substantial number of common shares and non-qualified stock options, indicating it's a small portion of his overall equity position.
Cytokinetics CEO to review performance after May 27 stockholder meeting
Cytokinetics will hold its Annual Meeting of Stockholders on May 27, 2026, at its headquarters in South San Francisco. Following the meeting, President and CEO Robert I. Blum will provide an overview of the company's performance. Stockholders of record as of March 31, 2026, are eligible to vote and attend, with a webcast made available for broader access.
Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics, Incorporated (Nasdaq: CYTK) announced that its Annual Meeting of Stockholders will take place on Wednesday, May 27, 2026, at 10:00 AM Pacific Time at the Company’s headquarters in South San Francisco. Following the meeting, President and CEO Robert I. Blum will provide an overview of Cytokinetics' performance. Stockholders of record as of March 31, 2026, are eligible to vote and attend.
How New Aficamten Phase 3 Data and Equity Raise Will Impact Cytokinetics (CYTK) Investors
Cytokinetics recently announced positive Phase 3 data for aficamten in obstructive and non-obstructive hypertrophic cardiomyopathy, alongside first-quarter 2026 results. The company also completed a US$700 million equity offering, which strengthens its financial position to fund commercialization and further trials, but also highlights ongoing dilution risk. This clinical success bolsters the investment narrative for aficamten's broader application, despite continued financial losses and the need for market access progress.
How New Aficamten Phase 3 Data and Equity Raise Will Impact Cytokinetics (CYTK) Investors
Cytokinetics (CYTK) recently announced positive Phase 3 data for its cardiac drug aficamten, covering both obstructive and non-obstructive hypertrophic cardiomyopathy. Despite robust Q1 2026 revenue of US$19.36 million, the company reported a net loss of US$206.03 million, necessitating a US$700 million equity raise to fund commercialization and trials. This data and capital infusion bolsters confidence in aficamten's market potential, but investors should remain aware of ongoing dilution risks due to continued losses.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics announced it granted stock options and restricted stock units to 8 new employees as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These grants include options to purchase 20,807 shares and 13,793 restricted stock units, with vesting schedules of 3 and 4 years respectively, subject to continued service. The company, a specialty cardiovascular biopharmaceutical firm, also highlighted its pipeline including MYQORZO® for oHCM and investigational medicines for heart failure.
Cytokinetics Inc stock (US2328281044): pipeline updates keep biotech in focus
Cytokinetics Inc. remains a key focus for biotech investors due to advances in its pipeline, particularly with its lead asset aficamten, a cardiac myosin inhibitor. The company's strategy involves developing precision medicines targeting cardiac muscle function for serious heart diseases. While Cytokinetics presents significant potential upside if its late-stage programs succeed, investors should be aware of the inherent clinical, regulatory, and financing risks associated with its business model.
GABELLI & Co INVESTMENT ADVISERS INC. Sells 23,900 Shares of Cytokinetics, Incorporated $CYTK
GABELLI & Co INVESTMENT ADVISERS INC. significantly reduced its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 63.8% in the fourth quarter, selling 23,900 shares, leaving it with 13,578 shares worth approximately $863,000. This comes as Cytokinetics reported matching earnings estimates but revenue that significantly beat expectations. Despite insider sales, analysts maintain a "Moderate Buy" rating with a consensus price target of $98.55.
Need To Know: Analysts Are Much More Bullish On Cytokinetics, Incorporated (NASDAQ:CYTK) Revenues
Analysts have significantly upgraded their near-term revenue forecasts for Cytokinetics, Incorporated (NASDAQ:CYTK), predicting US$108m in revenue for 2026, a 2.1% improvement, while holding loss per share steady at US$6.46. The consensus price target also increased by 13% to US$105, reflecting increased optimism despite the company remaining loss-making and growing slower than the broader industry. The upgrade is driven by an expectation for future growth that outpaces its past performance, although insider selling has been noted as a potential warning sign.
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
Cytokinetics will host its third annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on May 29, 2026, in San Francisco, CA. The symposium aims to foster collaboration and share innovative research in muscle biology, featuring expert speakers and poster presentations across cardiac, skeletal muscle biology, and emerging treatment modalities. The event is free but requires online registration by May 22, 2026.
Cytokinetics Inc stock (US2328281044): CLIMB muscle biology symposium adds to MYQORZO launch momentum
Cytokinetics Inc will host its third CLIMB muscle biology symposium on May 29, 2026, which is expected to extend the company's scientific and commercial momentum following the U.S. launch of MYQORZO and recent capital raises. The company's lead product, MYQORZO, a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy, has already generated $4.8 million in early revenue and received approvals in Europe and China. Investors are closely watching the upcoming PDUFA action date on November 14, 2026, for additional regulatory milestones and potential market expansion.
Cytokinetics president & CEO Blum sells $584,400 in common stock. By Investing.com
Robert I. Blum, President and CEO of Cytokinetics Inc. (NASDAQ:CYTK), sold 7,500 shares of common stock for $584,400. This transaction occurred on May 14, 2026, with shares priced at $77.92, close to its 52-week high after a 157% return, though InvestingPro analysis suggests the stock is currently overvalued. Blum retains over 400,000 direct shares and additional indirect holdings.
Cytokinetics president & CEO Blum sells $584,400 in common stock.
Cytokinetics President and CEO Robert I. Blum sold 7,500 shares of the company's common stock for $584,400. This sale occurred as the stock was near its 52-week high, following significant gains. The transaction is set against a backdrop of recent stock offerings, promising clinical trial results for the company's heart drug aficamten, and raised price targets from analysts.
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
Cytokinetics announced it will host its third annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on May 29, 2026, in San Francisco, CA. The symposium aims to foster collaboration and share innovative research in muscle biology, featuring expert speakers and poster presentations. Registration is open and free, with topics covering cardiac biology, skeletal muscle biology, and emerging treatment modalities for muscle diseases.
Free SF symposium probes new muscle, heart and weight-loss science
Cytokinetics (Nasdaq: CYTK) will host its third annual Contemporary Landscapes in Muscle Biology (CLIMB) symposium on May 29, 2026, in San Francisco. The free, capacity-limited event will feature a keynote by James A. Spudich, PhD, and sessions on cardiac and skeletal muscle biology and emerging treatments including genetic medicines and muscle preservation. The symposium aims to foster collaboration and advance understanding of muscle function and related diseases, with online registration closing on May 22, 2026.
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
Cytokinetics, Incorporated (Nasdaq: CYTK) announced it will host its third annual Contemporary Landscapes in Muscle Biology (CLIMB) Research Symposium on Friday, May 29, 2026, in San Francisco. This complimentary, limited-capacity event will bring together scientists and researchers to discuss innovations in muscle biology, covering cardiac biology, skeletal muscle biology, and emerging treatment modalities. The symposium aims to foster collaboration and advance the understanding and treatment of muscle-related diseases.
Investors Purchase High Volume of Call Options on Cytokinetics (NASDAQ:CYTK)
Cytokinetics (NASDAQ:CYTK) experienced a significant surge in call option trading volume, with 16,357 call options purchased, representing a 260% increase over typical volume. Several insiders sold shares totaling approximately $10.7 million, while institutional investors largely increased their stakes. The biopharmaceutical company reported strong revenue growth, exceeding expectations, and analysts maintain a "Moderate Buy" consensus rating with a target price of $98.55.
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Cytokinetics announced that members of its management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The event will be webcast live and archived on the company's website. Cytokinetics, a cardiovascular biopharmaceutical company, is advancing a pipeline of new medicines for cardiac muscle dysfunction, including approved MYQORZO® and investigational therapies like omecamtiv mecarbil and ulacamten.
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $97
J.P. Morgan has reiterated its Buy rating for Cytokinetics (CYTK.US) and increased the price target from $93 to $97. This adjustment reflects the firm's continued confidence in the biotechnology company's potential.
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Cytokinetics, Incorporated announced that its management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026, at 3:35 PM Eastern Time. Interested parties can access a live webcast of the event via the Investors & Media section of the company's website. The company will also archive webcast replays for 90 days following the event.
Growth Investors: Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 11%
Analysts have significantly upgraded their revenue forecasts for Cytokinetics, Incorporated (NASDAQ:CYTK) by 11%, leading to a 13% increase in the stock price and a 13% bump in the price target to US$105. While revenue is still expected to decline, the forecasted decline is less severe than historical trends and the wider industry. Despite concerns like insider selling, the recent upgrades suggest renewed optimism for the company's prospects.
Why Cytokinetics (CYTK) Is Up 12.9% After Strong Phase 3 MYQORZO HCM Data And Expanded Reach
Cytokinetics (CYTK) shares rose 12.9% following positive Phase 3 data for MYQORZO (aficamten) in both obstructive and non-obstructive hypertrophic cardiomyopathy, showing superior clinical outcomes and reassuring long-term safety. These results, coupled with real-world data, enhance MYQORZO’s clinical profile and expand its potential market reach. However, despite the strong data, investors are also weighing risks like potential commercialization lags, significant ongoing losses, and the dilutive effect of a recent US$805 million equity raise.
One Bay Area company scored $800 million around its heart drug. Here's another targeting the same condition
Braveheart Bio is developing a new heart drug, aiming to compete with larger pharmaceutical companies, following Cytokinetics' recent $800 million success. The upfront biopharmaceutical startup is positioning itself with a clinical trial in the crowded heart drug market.
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
Cytokinetics (Nasdaq: CYTK) presented new data at ESC Heart Failure 2026 for its heart drug MYQORZO (aficamten), highlighting its long-term safety and efficacy in treating hypertrophic cardiomyopathy (oHCM). The data demonstrated improved exercise capacity, favorable left atrial remodeling, and stable arrhythmia rates over 96 weeks, with MYQORZO outperforming metoprolol in several key metrics. The findings reinforce MYQORZO's clinical profile and address the significant unmet need and burden of HCM in both adult and pediatric patients.
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
Cytokinetics announced new data for its drug MYQORZO® (aficamten) at the ESC Heart Failure 2026 Congress, reinforcing its clinical profile and long-term safety for obstructive hypertrophic cardiomyopathy (oHCM). The data highlighted aficamten's superior performance over metoprolol, consistent benefits across sexes and dosages, and positive effects on left atrial mechanics. Real-world evidence presented also underscored the significant burden of HCM and the limitations of current therapies, emphasizing the need for effective treatments like aficamten, which is currently under investigation for pediatric oHCM.
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
Cytokinetics announced new data for its drug MYQORZO (aficamten) at the ESC Heart Failure 2026 Congress, reinforcing its clinical profile and long-term safety in patients with obstructive hypertrophic cardiomyopathy (oHCM). The presentations included analyses from three Phase 3 trials (SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM) showing MYQORZO's superior performance over metoprolol, consistent benefits across sexes, long-term safety, and positive effects on left atrium remodeling. The data also highlighted the significant burden of HCM and the unmet need for effective therapies.
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
Cytokinetics announced new data for its drug MYQORZO (aficamten) at the ESC Heart Failure 2026 Congress, reinforcing its favorable clinical profile and long-term safety. The data from Phase 3 trials (SEQUOIA-HCM, MAPLE-HCM) and an open-label extension (FOREST-HCM) demonstrated that MYQORZO outperformed metoprolol, showed consistent benefits across sexes, and improved left atrial mechanics. Additionally, real-world evidence highlighted the significant burden of hypertrophic cardiomyopathy (HCM) and the unmet need for effective therapies, including in pediatric patients.
Cytokinetics: Aficamten Has Momentum, But The Stock Is Too Expensive (NASDAQ:CYTK)
Cytokinetics has launched Myqorzo in the US, with promising early prescribing demand and positive Phase 3 trial results for aficamten in non-obstructive HCM. The company also has a strong cash position after a recent equity offering. However, the author finds the stock currently overvalued and suggests waiting for a dip before investing further.
Cytokinetics (NASDAQ: CYTK) prices $760.2M common stock sale at $71
Cytokinetics (NASDAQ: CYTK) successfully priced a public offering of 9,859,155 shares of its common stock at $71.00 per share, with underwriters fully exercising an option for an additional 1,478,873 shares. This offering generated approximately $760.2 million in net proceeds for the company, significantly increasing its cash resources. The capital was raised through an automatic shelf registration statement on Form S-3 and involved major underwriters including Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies.
$805M raised as Cytokinetics sells 11.3M shares at $71 each
Cytokinetics (Nasdaq: CYTK) announced the closing of an underwritten public offering, selling 11,338,028 common shares at $71.00 each for gross proceeds of approximately $805 million. This figure includes the full exercise of the underwriters' option to purchase additional shares. The company has a history of negative stock price reactions to offering announcements, with an average -5.22% one-day move following such events.
Cytokinetics Announces Closing of Public Offering of Common
Cytokinetics announced the closing of its underwritten public offering of 11,338,028 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares. The offering generated approximately $805 million in gross proceeds for the company, before deducting underwriting discounts and commissions. Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies acted as joint book-running managers.
Cytokinetics closes $805 million stock offering
Cytokinetics (NASDAQ:CYTK) has successfully completed an $805 million public stock offering, including the full exercise of underwriters' options, with shares priced at $71.00. This comes as the company's stock has surged 129% over the past year, although analysis suggests it may be overvalued. The offering follows strong Q1 2026 earnings driven by their cardiac myosin inhibitor MYQORZO, and positive analyst price target revisions.
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
Cytokinetics, Incorporated announced the closing of its underwritten public offering, including the full exercise of the underwriters’ option to purchase additional shares. The offering involved 11,338,028 shares of common stock at $71.00 per share, generating approximately $805 million in gross proceeds for the company. Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies acted as joint book-running managers for the offering.
Cytokinetics (NASDAQ: CYTK) prices 9.859M-share offering to raise $700M
Cytokinetics (NASDAQ: CYTK) has priced an offering of 9,859,155 shares of common stock at $71.00 per share, aiming to raise approximately $700 million in gross proceeds, or an estimated $661.0 million net after expenses. The underwriters have an option to purchase an additional 1,478,873 shares. The company plans to use the net proceeds for the commercial launch of MYQORZO, advancing its pipeline, and general corporate purposes.
In a heart disease with no approved drugs, aficamten hits Phase 3 goals
Cytokinetics announced positive topline results for its pivotal Phase 3 trial, ACACIA-HCM, investigating aficamten for symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). The trial successfully met both dual primary endpoints, demonstrating statistically significant improvements in KCCQ-CSS and pVO2 compared to placebo. While no new safety signals were identified, 10% of aficamten participants experienced Left Ventricular Ejection Fraction (LVEF) below 50%, compared to 1% in the placebo group, with two serious heart failure events reported.
Earnings Update: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Are Boosting Their Estimates
Cytokinetics, Incorporated (NASDAQ:CYTK) saw its shares jump 26% after reporting first-quarter revenues of US$19m, significantly beating estimates. Analysts have adjusted their forecasts, raising revenue expectations for 2026 to US$97.6m while maintaining loss per share estimates at US$6.51. The consensus price target increased to US$102, although wide variations in analyst targets suggest differing future outlooks for the company.
Cytokinetics Announces Pricing of $700 Million Public Offering of Common Stock
Cytokinetics has priced a public offering of 9,859,155 shares of common stock at $71.00 per share, aiming to raise approximately $700 million. The offering, expected to close on May 8, 2026, includes an option for underwriters to purchase additional shares. Major financial institutions such as Morgan Stanley and Goldman Sachs are managing the offering, which will help fund Cytokinetics' continued development of medicines for cardiac muscle dysfunction.
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
Cytokinetics announced the pricing of an upsized public offering of 9,859,155 shares of common stock at $71.00 per share, expecting to generate approximately $700 million in gross proceeds. The offering is anticipated to close on May 8, 2026, and the company has granted underwriters a 30-day option to purchase additional shares. Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies are acting as joint book-running managers.
Cytokinetics prices nearly 9.9M-share sale at $71 a share
Cytokinetics (Nasdaq: CYTK) has priced an upsized underwritten public offering of 9,859,155 common shares at $71.00 per share, aiming to raise approximately $700 million in gross proceeds. The offering, expected to close on May 8, 2026, also includes a 30-day option for underwriters to purchase an additional 1,478,873 shares. This move is consistent with the company's past financing strategies to fund development and commercialization, although previous offerings have typically led to short-term negative stock reactions due to dilution.
FMR LLC increases stake in Cytokinetics (NASDAQ: CYTK) to 9.0%
FMR LLC has filed an Amendment No. 7 to a Schedule 13G/A, reporting a beneficial ownership of 11,135,192.23 shares of Cytokinetics Inc. common stock, which represents 9.0% of the class as of March 31, 2026. The filing indicates FMR LLC has sole dispositive power over these shares and sole voting power over 11,093,544.96 shares. The document was signed by Richard Bourgelas, authorized under a Power of Attorney, and also referenced Abigail P. Johnson.
Truist raises Cytokinetics stock price target on positive trial data
Truist Securities increased its price target for Cytokinetics (NASDAQ:CYTK) shares to $106 from $92, maintaining a Buy rating, following positive data from the company's ACACIA trial for its cardiac myosin inhibitor, aficamten. The data suggests aficamten could become a dominant treatment for hypertrophic cardiomyopathy, particularly in the non-obstructive indication where it has shown statistically significant improvements. This upgrade aligns with recent strong Q1 2026 earnings and another price target increase by RBC Capital, reflecting Cytokinetics' successful transition to a commercial-stage biopharmaceutical company.
Fresh off big clinical trial win, Cytokinetics looks to raise about $650 million
Cytokinetics is planning to raise approximately $650 million through a stock sale, following a significant clinical trial victory and successful initial sales for its drug Myqorzo. The company is also preparing for a European launch, contributing to its strong position. This move aims to secure funding for the continued development and commercialization of its therapies.
Cytokinetics stock hits 52-week high after ACACIA-HCM trial
Cytokinetics (CKMT) shares reached a new 52-week high following the announcement of positive results from its ACACIA-HCM trial. The trial's success has positively impacted investor confidence and stock performance.
RBC Capital raises Cytokinetics stock price target on strong launch
RBC Capital has increased its price target for Cytokinetics Inc. shares to $119 from $101, maintaining an Outperform rating due to the strong growth trends of Myqorzo and the substantial opportunity in nHCM. This adjustment follows Cytokinetics' first-quarter 2026 earnings report, which showed significant revenue growth, and reflects the company's successful transition from clinical to commercial stage. Despite a recent surge in stock price, InvestingPro analysis indicates the stock is currently overvalued compared to its Fair Value.
Cytokinetics scores late-stage win in non-obstructive HCM as BMS plans Camzyos restart
Cytokinetics announced positive Phase III results for Myqorzo aficamten in non-obstructive hypertrophic cardiomyopathy (HCM), causing its shares to rise. This represents a significant achievement in an indication where drug development has historically been challenging. The news also impacts Bristol Myers Squibb's plans for Camzyos, which previously failed a late-stage trial in the same indication but is now slated for a development restart.
Cytokinetics EVP Malik sells $270,795 in company stock
Malik Fady Ibraham, EVP of Research & Development at Cytokinetics Inc. (NASDAQ:CYTK), sold 3,500 shares for $270,795 after exercising non-qualified stock options. Following these transactions, Ibraham directly holds 153,902 shares and 51,386 non-qualified stock options. This sale follows the company's recent reporting of a significant increase in Q1 2026 revenue to $19.4 million, primarily due to the successful launch of MYQORZO.
Cytokinetics (NASDAQ: CYTK) details MYQORZO rollout and $1.1B cash
Cytokinetics (NASDAQ: CYTK) provided a corporate presentation detailing the launch of MYQORZO (aficamten), its cardiovascular pipeline, and strong financial position, including approximately $1.1 billion in cash as of March 31, 2026. The company highlighted MYQORZO's FDA approval for obstructive hypertrophic cardiomyopathy (oHCM), recent launches in the U.S., China, and EU, and key launch metrics such as prescriber certifications and patient uptake. Additionally, Cytokinetics outlined its late-stage pipeline programs, including aficamten in non‑obstructive HCM, omecamtiv mecarbil in heart failure with reduced ejection fraction, and ulacamten in HFpEF, along with 2026 regulatory milestones like the aficamten sNDA PDUFA date of November 14, 2026.
